Dr. Sodroski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Avenue
CLSB 1010
Boston, MA 02215Phone+1 617-632-3371Fax+1 617-632-4338
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1980
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Publications & Presentations
PubMed
- 1606 citationsThe lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.Conrad C. Bleul, Michael Farzan, Hyeryun Choe, Cristina Parolin, Ian Clark-Lewis
Nature. 1996-08-29 - 97 citationsTRIM5α Modulates Immunodeficiency Virus Control in Rhesus MonkeysSo-Yon Lim, Thomas F. Rogers, Tiffany Chan, James B. Whitney, Jonghwa Kim
Plos Pathogens. 2010-01-22 - 1482 citationsThe cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.Matthew Stremlau, Christopher M. Owens, Michel Perron, Michael Kiessling, Patrick Autissier
Nature. 2004-02-26
Journal Articles
- Conformational Differences Between Functional Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Trimers and Stabilized Soluble TrimersJoseph Sodroski, MD, mBio
- SOSIP Changes Affect Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformation and CD4 EngagementJoseph Sodroski, MD, mBio
- Contribution of the gp120 V3 Loop to Envelope Glycoprotein Trimer Stability in Primate Immunodeficiency VirusesJoseph Sodroski, MD, ScienceDirect
Press Mentions
- Flossie Wong-Staal Helped Unlock Mysteries of HIVJuly 24th, 2020
- TRIM5α Cytoplasmic Bodies Are Highly Dynamic StructuresMarch 28th, 2007
Grant Support
- Broad-Range Inhibitors Of Human Immunodeficiency Virus EntryNational Institute On Drug Abuse2012
- Single-Particle Reconstruction Of HIV-1 Envelope Glycoprotein TrimersNational Institute Of Allergy And Infectious Diseases2011–2012
- Antiretroviral Activity Of Trim5alphaNational Institute Of Allergy And Infectious Diseases2005–2012
- HIV-1 Envelope GlycoproteinsNational Institute Of Allergy And Infectious Diseases1996–2012
- Structure-Based Antagonism Of HIV-1 Envelope Function In Cell EntryNational Institute Of General Medical Sciences2007–2011
- Structure Of The Retroviral Restriction Factor, Trim5alphaNational Institute Of Allergy And Infectious Diseases2007–2008
- Molecular Studies Of HIV1 Neutralizing AntibodiesNational Institute Of Allergy And Infectious Diseases1998–2007
- Structural Analysis Of HIV1 Envelope GlycoproteinsNational Institute Of Allergy And Infectious Diseases1997–2006
- Molecular Interaction Between HIV1 Gp120-Cd4 ComplexesNational Institute Of Allergy And Infectious Diseases1997–2006
- A Study To Determine The Replicative/Pathologic Ability Of Chimeric SIV/HIVNational Center For Research Resources2004
- HIV-1 Oligomeric Envelope-ProteoliposomesNational Institute Of Allergy And Infectious Diseases2002–2004
- Topological Analysis Of HIV-1 Envelope GlycoproteinsNational Institute Of Allergy And Infectious Diseases2000–2004
- Replication And Pathogenicity Of HIV/SIV ChimeraeNational Institute Of Allergy And Infectious Diseases1999–2004
- Dfci-Bidmc-Ch Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases1999–2003
- Adaption Of HIV Vectors To NonprimatesNational Heart, Lung, And Blood Institute2000–2002
- Core--Developmental FacilityNational Institute Of Allergy And Infectious Diseases1999–2002
- Core--Biohazard Containment FacilityNational Institute Of Allergy And Infectious Diseases1999–2002
- Core--Virology And Biology FacilityNational Institute Of General Medical Sciences1997–2002
- Vaccine Vectors Based On HIV-1National Institute Of Allergy And Infectious Diseases1999–2000
- Developmental CoreNational Institute Of Allergy And Infectious Diseases1996–1998
- Core--Biohazard ContainmentNational Institute Of Allergy And Infectious Diseases1996–1998
- AIDS ResearchNational Institute Of Allergy And Infectious Diseases1994–1998
- Replication And Pathogenicity Of HIV/SIV ChimerasNational Institute Of Allergy And Infectious Diseases1993–1998
- Molecular Studies Of HIV 1 Neutralizing AntibodiesNational Institute Of Allergy And Infectious Diseases1994–1997
- HIV 1 Envelope GlycoproteinsNational Institute Of Allergy And Infectious Diseases1996
- Model To Evaluate Requirements For HIV-1 ProphylaxisNational Institute Of Allergy And Infectious Diseases1994–1996
- HIV-1 Envelope GlycoproteinsNational Institute Of Allergy And Infectious Diseases1993–1995
- Screening And Drug Design Of HIV-1 TherapeuticsNational Institute Of Allergy And Infectious Diseases1993–1994
- Pathogenic Provirus Of SivmacNational Institute Of Allergy And Infectious Diseases1993–1994
- Molecular Characterization Of Monoclonal AntibodiesNational Institute Of Allergy And Infectious Diseases1991–1993
- Development Of HIV As A Vector SystemNational Institute Of Allergy And Infectious Diseases1989–1993
- Role Of The HIV-1 Envelope Glycoproteins In ReplicationNational Institute Of Allergy And Infectious Diseases1990–1992
- Role Of Glycosylation In HIV Envelope ImmunogenicityNational Institute Of Allergy And Infectious Diseases1989–1991
- Role Of The HTLV-III Envelope Glycoprotein In VirusNational Institute Of Allergy And Infectious Diseases1987–1989
- Role Of HTLV LOR Region In Transcriptional RegulationNational Cancer Institute1985–1987
- Expression And Potential Function Of BLV LTR RegionNational Cancer Institute1985–1987
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: